



Special Board of Directors Meeting

26 May 2025

MS Teams Video-Conference

Phase 1b/2 Clinical trial for CLE experimental drug

The Board voted to approve a Phase 1b/2 Clinical trial for CLE experimental drug.

Research relating to Cree Leukoencephalopathy (CLE) is a priority, as CLE is a deadly genetic condition affecting infants in Eeyou Istchee. The Research Governance Committee has reviewed and endorsed a preliminary proposal from principal investigator Dr. Genevieve Bernard, concerning participating in a clinical trial for testing an experimental drug that could improve clinical outcomes of children with CLE. One child is currently receiving this treatment on a compassionate basis and the proposal is to extend the clinical trial to other children in Eeyou Istchee, should their parents approve the use of this treatment for their child.



NEXT REGULAR BOARD MEETING

June 2025





CREEHEALTH.ORG